One Size Fits One: Pharmacogenetics in Gastroenterology

Abrahams, 2009, The case for personalized medicine, J Diabetes Sci Technol, 3, 680, 10.1177/193229680900300411 Abrahams, 2005, The Personalized Medicine Coalition: goals and strategies, Am J Pharmacogenomics, 5, 345, 10.2165/00129785-200505060-00002 Zhou, 2008, Clinical pharmacogenetics and potential application in personalized medicine, Curr Drug Metab, 9, 738, 10.2174/138920008786049302 Shin, 2013, Pharmacokinetics and pharmacodynamics of the proton pump inhibitors, J Neurogastroenterol Motil, 19, 25, 10.5056/jnm.2013.19.1.25 Schwab, 2004, CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori, Clin Pharmacol Ther, 76, 201, 10.1016/j.clpt.2004.05.002 Hagymasi, 2011, Update on the pharmacogenomics of proton pump inhibitors, Pharmacogenomics, 12, 873, 10.2217/pgs.11.4 Sohn, 1997, Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status, Clin Pharmacol Ther, 61, 574, 10.1016/S0009-9236(97)90137-5 Shimatani, 2006, Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19, Clin Pharmacol Ther, 79, 144, 10.1016/j.clpt.2005.09.012 Desta, 2002, Clinical significance of the cytochrome P450 2C19 genetic polymorphism, Clin Pharmacokinet, 41, 913, 10.2165/00003088-200241120-00002 The use of medicines in the United States: review of 2010, report by the IMS Institute for Healthcare Informatics. 2011. Available at: http://www.imshealth.com/imshealth/Global/Content/IMS%20Institute/Documents/IHII_UseOfMed_report%20.pdf. Accessed January 20, 2014. Fang, 2008, Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects, Pharmacotherapy, 28, 42, 10.1592/phco.28.1.42 Beorlegui, 2000, Potential interaction between methotrexate and omeprazole, Ann Pharmacother, 34, 1024, 10.1345/aph.19094 Bezabeh, 2012, Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors, Oncologist, 17, 550, 10.1634/theoncologist.2011-0431 Zhao, 2012, Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole, Ther Drug Monit, 334, 739, 10.1097/FTD.0b013e318271b6e6 Hosohata, 2009, Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients, Drug Metab Dispos, 37, 821, 10.1124/dmd.108.025833 Hosohata, 2008, Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5, Drug Metab Pharmacokinet, 23, 134, 10.2133/dmpk.23.134 Pauli-Magnus, 2001, Interaction of omeprazole, lansoprazole, and pantoprazole with P-glycoprotein, Naunyn Schmiedebergs Arch Pharmacol, 364, 551, 10.1007/s00210-001-0489-7 Drepper, 2012, Clopidogrel and proton pump inhibitors: where do we stand in 2012?, World J Gastroenterol, 18, 2161, 10.3748/wjg.v18.i18.2161 Caraco, 1995, Interethnic difference in omeprazole's inhibition of diazepam metabolism, Clin Pharmacol Ther, 58, 62, 10.1016/0009-9236(95)90073-X Dixit, 2001, Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers, Methods Find Exp Clin Pharmacol, 23, 37, 10.1358/mf.2001.23.1.619178 Frick, 2003, Omeprazole reduced clozapine plasma concentrations: a case report, Pharmacolpsychiatry, 36, 121, 10.1055/s-2003-39980 U.S. Food and Drug Administration. FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs. 2009. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm149533.htm. Accessed January 20, 2014. Zanger, 2001, Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6, Pharmacogenetics, 11, 573, 10.1097/00008571-200110000-00004 Parkman, 2012, Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters, J Clin Gastroenterol, 46, 494, 10.1097/MCG.0b013e3182522624 van der Padt, 2006, Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms, Neth J Med, 64, 160 Ganzini, 1993, The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders, Arch Intern Med, 153, 1469, 10.1001/archinte.1993.00410120051007 Sewell, 1992, Metoclopramide-associated tardive dyskinesia: an analysis of 67 cases, Arch Fam Med, 1, 271, 10.1001/archfami.1.2.271 Quigley, 2011, Cisapride: what can we learn from the rise and fall of a prokinetic?, J Dig Dis, 12, 147 Desta, 2000, Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies, Drug Metab Dispos, 28, 789 Bohets, 2000, Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions, Br J Pharmacol, 129, 1655, 10.1038/sj.bjp.0703246 Mohammad, 1997, Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride, Am J Physiol, 273, H2534 Drolet, 1998, Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval, Circulation, 97, 204, 10.1161/01.CIR.97.2.204 Osterman, 2006, Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis, Gastroenterology, 130, 1047, 10.1053/j.gastro.2006.01.046 Stocco, 2014, Deletion of glutathione-S-transferase M1 reduces azathioprine metabolite concentrations in young patients with inflammatory bowel disease, J Clin Gastroenterol, 48, 43, 10.1097/MCG.0b013e31828b2866 Bertilsson, 1995, Geographical/interracial differences in polymorphic drug oxidation, Clin Pharmacokinet, 29, 192, 10.2165/00003088-199529030-00005 Cotton, 2000, Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review, Am J Epidemiol, 151, 7, 10.1093/oxfordjournals.aje.a010124 Weinshilboum, 1980, Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity, Am J Hum Genet, 32, 651 Garat, 2008, Characterisation of novel defective thiopurine S-methyltransferase allelic variants, Biochem Pharmacol, 76, 404, 10.1016/j.bcp.2008.05.009 Gisbert, 2009, Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review, Am J Gastroenterol, 104, 760 Billioud, 2011, Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review, Am J Gastroenterol, 106, 674, 10.1038/ajg.2011.60 Sandborn, 1996, Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study, Mayo Clin Proc, 71, 431, 10.4065/71.5.431 Esters, 2002, Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease, Am J Gastroenterol, 97, 1458, 10.1111/j.1572-0241.2002.05689.x Taylor, 2001, ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease, Gastroenterology, 120, 1347, 10.1053/gast.2001.23966 Hugot, 2001, Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease, Nature, 411, 599, 10.1038/35079107 Ogura, 2001, A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease, Nature, 411, 603, 10.1038/35079114 Mascheretti, 2002, Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials, Pharmacogenetics, 12, 509, 10.1097/00008571-200210000-00002 Vermeire, 2002, NOD2/CARD15 does not influence response to infliximab in Crohn's disease, Gastroenterology, 123, 106, 10.1053/gast.2002.34172 Pierik, 2004, Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab, Aliment Pharmacol Ther, 20, 303, 10.1111/j.1365-2036.2004.01946.x Louis, 2002, A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism, Scand J Gastroenterol, 37, 818, 10.1080/gas.37.7.818.824 Louis, 2004, Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease, Aliment Pharmacol Ther, 19, 511, 10.1111/j.1365-2036.2004.01871.x McGeough, 2012, Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy, Rheumatol Int, 32, 1647, 10.1007/s00296-011-1838-6 Mesko, 2013, Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease, Genome Med, 5, 59, 10.1186/gm463 Dubinsky, 2010, Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease, Inflamm Bowel Dis, 16, 1357, 10.1002/ibd.21174 Arijs, 2009, Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis, Gut, 58, 1612, 10.1136/gut.2009.178665 Arijs, 2010, Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease, Inflamm Bowel Dis, 16, 2090, 10.1002/ibd.21301 Arijs, 2011, Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment, Am J Gastroenterol, 106, 748, 10.1038/ajg.2011.27 Afif, 2010, Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease, Am J Gastroenterol, 105, 1133, 10.1038/ajg.2010.9 Chiu, 2013, Serum adalimumab concentration and clinical remission in patients with Crohn's disease, Inflamm Bowel Dis, 19, 1112, 10.1097/MIB.0b013e3182813242 Hamburg, 2010, The path to personalized medicine, N Engl J Med, 363, 301, 10.1056/NEJMp1006304 Collins, 2013, First FDA authorization for next-generation sequencer, N Engl J Med, 369, 2369, 10.1056/NEJMp1314561 U.S. Food and Drug Administration. Inspections, compliance, enforcement, and criminal investigations 23andMe, Inc. 2013. Available at: http://www.fda.gov/iceci/enforcementactions/warningletters/2013/ucm376296.htm. Accessed November 22, 2013. Gharani, 2013, The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system, Genome Med, 5, 93, 10.1186/gm499 Flockhart D. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine, 2007. Available at: http://medicine.iupui.edu/clinpharm/ddis/main-table/. Accessed January 20, 2014. Relling, 2011, Pharmacogenetics: call to action, Clin Pharmacol Ther, 90, 507, 10.1038/clpt.2011.172 Swen, 2011, Pharmacogenetics: from bench to byte—an update of guidelines, Clin Pharmacol Ther, 89, 662, 10.1038/clpt.2011.34 Lee, 2010, Has the microbiota played a critical role in the evolution of the adaptive immune system?, Science, 330, 1768, 10.1126/science.1195568 Iida, 2013, Commensal bacteria control cancer reponse to therapy by modulating the tumor microenvironment, Science, 342, 967, 10.1126/science.1240527 Maliepaard, 2013, Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective, Nat Rev Drug Discov, 12, 103, 10.1038/nrd3931